QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.55%)
BABA   74.68 (-2.68%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.71%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+6.86%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.55%)
BABA   74.68 (-2.68%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.71%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+6.86%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.55%)
BABA   74.68 (-2.68%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.71%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+6.86%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.55%)
BABA   74.68 (-2.68%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.71%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+6.86%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)

Gilead Sciences Stock Price, News & Analysis (NASDAQ:GILD)

+0.72 (+0.97%)
(As of 11/29/2023 ET)
Today's Range
50-Day Range
52-Week Range
5.09 million shs
Average Volume
5.75 million shs
Market Capitalization
$93.74 billion
P/E Ratio
Dividend Yield
Price Target

Gilead Sciences MarketRank™ Stock Analysis

Analyst Rating
2.25 Rating Score
17.3% Upside
$88.22 Price Target
Short Interest
1.46% of Shares Sold Short
Dividend Strength
Based on Four Factors
Upright™ Environmental Score
News Sentiment
0.61mentions of Gilead Sciences in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$515,562 Sold Last Quarter
Proj. Earnings Growth
From $6.75 to $7.44 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.40 out of 5 stars

Medical Sector

3rd out of 949 stocks

Biological Products, Except Diagnostic Industry

1st out of 156 stocks

GILD stock logo

About Gilead Sciences Stock (NASDAQ:GILD)

Gilead Sciences, Inc. is a leading biopharmaceutical company in Foster City, California. Founded in 1987, the company's mission is to develop innovative medicines that address unmet medical needs and improve the lives of people around the world. Gilead focuses on discovering, developing, and commercializing therapies in HIV/AIDS, liver diseases, oncology, inflammatory and respiratory diseases, and cardiovascular conditions. 

Gilead's portfolio includes a wide range of products and therapies, with its most notable product being Truvada, a leading medication for HIV prevention. The company also offers other HIV treatments, such as Biktarvy and Descovy. In addition to its HIV franchise, Gilead has significantly advanced in treating chronic hepatitis B and C with drugs like Veklury and Epclusa. Furthermore, the company has expanded into oncology with therapies such as Trodelvy and Yescarta.

Gilead Sciences is led by experienced executives who bring industry knowledge and expertise. The company's Chief Executive Officer, Daniel O'Day, joined Gilead in 2019 and has a proven track record in the pharmaceutical industry. O'Day previously served as the CEO of Roche Pharmaceuticals, where he successfully led the company through significant growth.

Gilead Sciences has consistently delivered a solid financial performance in recent years. The company has reported strong revenue and net income numbers yearly. This growth was primarily driven by solid sales of Gilead's HIV and liver disease therapies. The company averages a profit margin between 25% - 30%. Gilead has maintained a healthy balance sheet with manageable levels of debt. Gilead's strong financial position allows it to invest in research and development initiatives and pursue strategic acquisitions to drive future growth.

Investor sentiment towards Gilead has improved in recent years due to the company's strong financial performance and promising pipeline of innovative therapies. The successful launch of new products, such as Trodelvy and Biktarvy, has further bolstered investor confidence in Gilead's growth prospects.

Gilead Sciences operates in the highly competitive biopharmaceutical industry, characterized by rapid innovation, high research and development costs, and stringent regulatory requirements. The industry is subject to evolving market dynamics, including changing reimbursement policies, patent expirations, and intense competition from established and emerging biotech firms.

Gilead's expansion into oncology has been promising, with the introduction of therapies targeting specific types of cancer. However, the oncology market is highly competitive, with several significant players and emerging biotechs vying for market share. Gilead's success in this area will depend on its ability to differentiate its products, demonstrate clinical efficacy, and navigate the evolving treatment landscape.

Gilead Sciences has identified several growth opportunities that can contribute to its future success. One key focus is expanding its product portfolio through internal research and development efforts and strategic acquisitions and partnerships. By investing in innovative therapies, Gilead aims to address unmet medical needs and strengthen its competitive position.

The company's pipeline includes potential breakthrough treatments for various diseases, including novel antiviral agents, immunology candidates, and cell therapies. Gilead also explores combination therapies to enhance treatment outcomes and extend its market reach. These advancements provide opportunities for revenue growth and market expansion.

Gilead Sciences faces risks and challenges that could impact its performance and prospects. One of the primary challenges for Gilead is the potential for generic competition. As patents on some of its key products expire, there is a risk of generic manufacturers entering the market with lower-priced alternatives. This can lead to pricing pressures and a decline in market share for Gilead's established therapies. The company must continue to innovate and develop new drugs to mitigate the impact of generic competition.

Another challenge is the evolving regulatory environment. Changes in healthcare policies, pricing regulations, and reimbursement systems can significantly impact the profitability of pharmaceutical companies. Gilead operates in multiple regions and must navigate various regulatory frameworks, which can introduce uncertainties and challenges to its business operations.

Additionally, Gilead faces intense competition from established pharmaceutical and smaller biotech firms. Rapid technological advancements and evolving treatment paradigms characterize the industry. Competitors may develop new therapies or gain regulatory approvals threatening Gilead's market share. The company must continue to invest in research and development to maintain its competitive edge.

Clinical trial failures and delays are also inherent risks in the biopharmaceutical industry. Despite rigorous research and development processes, there is always a possibility that promising drug candidates may fail to meet efficacy or safety requirements during clinical trials. These setbacks can result in significant financial losses and delays in product launches, impacting Gilead's revenue streams.

Additionally, Gilead faces the challenge of addressing changing treatment landscapes and shifting patient preferences. Medical advancements, scientific discoveries, and evolving disease patterns can alter the demand for specific therapies. Gilead must anticipate and adapt to these changes to ensure its products remain relevant and effective.

Risk management is crucial for Gilead Sciences to mitigate potential challenges. The company employs rigorous clinical trial protocols, invests in diverse therapeutic areas, and pursues strategic partnerships to diversify its product portfolio. Gilead's strong financial position allows it to navigate uncertainties and invest in research and development initiatives. Furthermore, the company monitors regulatory developments and engages with policymakers to shape favorable healthcare policies.

GILD Stock Price History

GILD Stock News Headlines

J&J, Gilead, BMS: A look at undervalued dividend payers (GILD)
J&J, Gilead and Bristol Myers are among healthcare stocks with defensive qualities amid market volatility and a potential economic slowdown
Buying the dip in high-yield Gilead Sciences 
Pharma stock Gilead Sciences is well-positioned for the next few years with a growing core business, a healthy pipeline, and cash flow to sustain capital return
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Gilead's Ambition: To Help End the HIV Epidemic
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Gilead Sciences: Slow Progress, But Progress Altogether
Truist Financial Keeps Their Buy Rating on Gilead Sciences (GILD)
Gilead Sciences declares $0.75 dividend
Q3 2023 Gilead Sciences Inc Earnings Call
AHF Slams Gilead Profiteering
See More Headlines
Receive GILD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gilead Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 9/28 Dividend
Dividend Payable
Last Earnings
Ex-Dividend for 12/28 Dividend
Dividend Payable
Fiscal Year End
Next Earnings (Estimated)

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
16 Analysts


Net Income
$4.59 billion
Pretax Margin


Sales & Book Value

Annual Sales
$27.28 billion
Cash Flow
$8.99 per share
Book Value
$17.85 per share


Outstanding Shares
Free Float
Market Cap
$93.47 billion

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Daniel P. O'Day (Age 59)
    Chairman & CEO
    Comp: $7.27M
  • Mr. Andrew D. DickinsonMr. Andrew D. Dickinson (Age 53)
    Executive VP & CFO
    Comp: $2.94M
  • Ms. Deborah H. Telman (Age 58)
    Executive VP of Corporate Affairs, General Counsel & Corporate Secretary
    Comp: $2.32M
  • Ms. Johanna MercierMs. Johanna Mercier (Age 53)
    Chief Commercial Officer
    Comp: $3.32M
  • Dr. Merdad V. Parsey M.D. (Age 60)
    Ph.D., Chief Medical Officer
    Comp: $3.07M
  • Ms. Sandra Patterson (Age 56)
    Senior VP, Corporate Controller & Principal Accounting Officer
  • Ms. Jacquie Ross C.F.A.
    Vice President of Investor Relations
  • Ms. Jyoti K. Mehra (Age 47)
    Executive Vice President of Human Resources
  • Dr. Linda Slanec Higgins Ph.D. (Age 61)
    Senior Vice President of Research, Innovation & Portfolio
  • Dr. Rudolf Ertl (Age 77)
    Senior Vice President of Commercial Operations of Australia, Canada, Europe

Should I Buy Gilead Sciences Stock? GILD Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Gilead Sciences was last updated on Thursday, November 16, 2023 at 12:00 AM.


Here are some ways that investors could benefit from investing in Gilead Sciences, Inc.:

  • Gilead Sciences has established a partnership with Assembly Biosciences to develop next-generation therapeutics for serious viral diseases. This collaboration could lead to the development of innovative treatments that address unmet medical needs and potentially generate significant revenue for the company.
  • Gilead Sciences is advancing global health equity in tropical regions. By focusing on improving healthcare in underserved areas, the company can expand its market reach and contribute to positive social impact.
  • Gilead Sciences has a strong track record in the pharmaceutical industry. With a history of successful drug development and commercialization, the company has demonstrated its ability to deliver value to investors.
  • The current stock price of Gilead Sciences, Inc. is favorable for investors looking for potential growth opportunities. The stock price reflects the market's perception of the company's future prospects and can be an attractive entry point for investors.
  • Gilead Sciences has a diverse portfolio of products targeting various therapeutic areas, including HIV, hepatitis, and oncology. This diversification reduces the company's reliance on a single product and provides a more stable revenue stream.


Investors should be bearish about investing in Gilead Sciences, Inc. for these reasons:

  • Gilead Sciences faces intense competition in the pharmaceutical industry. The company operates in a highly competitive market where other pharmaceutical companies are also developing innovative treatments. This competition can impact Gilead's market share and profitability.
  • The company's revenue growth has been relatively slow in recent periods. Investors should carefully evaluate the company's ability to drive revenue growth and maintain profitability in the face of market challenges.
  • Gilead Sciences is subject to regulatory risks. Changes in regulations and policies related to drug pricing, approvals, and reimbursement can significantly impact the company's financial performance.
  • The company's success heavily relies on the success of its research and development efforts. Failure to develop and commercialize new drugs or therapies could negatively impact Gilead's future growth prospects.
  • Investors should consider the potential impact of any negative news or developments related to Gilead Sciences, such as legal disputes, safety concerns, or negative clinical trial results. These factors can affect the company's reputation and stock performance.

GILD Stock Analysis - Frequently Asked Questions

Should I buy or sell Gilead Sciences stock right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 1 sell rating, 10 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GILD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GILD, but not buy additional shares or sell existing shares.
View GILD analyst ratings
or view top-rated stocks.

What is Gilead Sciences' stock price target for 2024?

16 Wall Street research analysts have issued 12 month target prices for Gilead Sciences' shares. Their GILD share price targets range from $71.00 to $105.00. On average, they predict the company's share price to reach $88.22 in the next twelve months. This suggests a possible upside of 17.3% from the stock's current price.
View analysts price targets for GILD
or view top-rated stocks among Wall Street analysts.

How have GILD shares performed in 2023?

Gilead Sciences' stock was trading at $85.85 on January 1st, 2023. Since then, GILD shares have decreased by 12.4% and is now trading at $75.23.
View the best growth stocks for 2023 here

Are investors shorting Gilead Sciences?

Gilead Sciences saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 18,130,000 shares, a decrease of 7.0% from the October 31st total of 19,500,000 shares. Based on an average daily trading volume, of 5,540,000 shares, the days-to-cover ratio is presently 3.3 days.
View Gilead Sciences' Short Interest

When is Gilead Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 1st 2024.
View our GILD earnings forecast

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) posted its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported $2.29 EPS for the quarter, topping the consensus estimate of $1.91 by $0.38. The biopharmaceutical company earned $7.05 billion during the quarter, compared to analysts' expectations of $6.81 billion. Gilead Sciences had a net margin of 21.45% and a trailing twelve-month return on equity of 39.30%. The firm's revenue for the quarter was up .1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.90 EPS.
Read the conference call transcript

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences announced a quarterly dividend on Wednesday, November 1st. Stockholders of record on Friday, December 15th will be given a dividend of $0.75 per share on Thursday, December 28th. This represents a $3.00 dividend on an annualized basis and a yield of 3.99%. The ex-dividend date is Thursday, December 14th.
Read our dividend analysis for GILD

Is Gilead Sciences a good dividend stock?

Gilead Sciences (NASDAQ:GILD) pays an annual dividend of $3.00 per share and currently has a dividend yield of 4.00%. GILD has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company has been increasing its dividend for 8 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 64.38%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, GILD will have a dividend payout ratio of 40.32% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for GILD.

What guidance has Gilead Sciences issued on next quarter's earnings?

Gilead Sciences issued an update on its FY23 earnings guidance on Tuesday, November, 7th. The company provided earnings per share guidance of 6.65-6.85 for the period, compared to the consensus earnings per share estimate of $6.63.

What is Daniel O’Day's approval rating as Gilead Sciences' CEO?

107 employees have rated Gilead Sciences Chief Executive Officer Daniel O’Day on Glassdoor.com. Daniel O’Day has an approval rating of 92% among the company's employees. This puts Daniel O’Day in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Gilead Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include NVIDIA (NVDA), Walt Disney (DIS), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), Netflix (NFLX) and Johnson & Johnson (JNJ).

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (1.54%), Morgan Stanley (1.36%), Bank of New York Mellon Corp (1.23%), Northern Trust Corp (1.20%), Parnassus Investments LLC (0.96%) and Legal & General Group Plc (0.84%). Insiders that own company stock include Andrew D Dickinson, Brett A Pletcher, Diane E Wilfong, Diane E Wilfong, Johanna Mercier, Merdad Parsey and Richard James Whitley.
View institutional ownership trends

How do I buy shares of Gilead Sciences?

Shares of GILD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Gilead Sciences have any subsidiaries?
The following companies are subsidiares of Gilead Sciences: Arresto BioSciences, Asegua Therapeutics LLC, CGI Pharmaceuticals, CV Therapeutics, Calistoga Pharmaceuticals, Cell Design Labs, Corus Pharma, Cytopia Pty. Ltd., EpiTherapeutics ApS, Epitherapeutics, Forty Seven, Forty Seven Holdings LLC, Forty Seven Inc., Fosun Pharma Kite Biotechnology Co. Ltd., Gilead Alberta LLC, Gilead Alberta ULC, Gilead Apollo LLC, Gilead Apollo Unlimited Company, Gilead Biopharmaceutics Ireland UC, Gilead Biopharmaceutics US LLC, Gilead Calistoga LLC, Gilead Connecticut Inc., Gilead Holdings LLC, Gilead Ireland Research UC, Gilead Oncology Ireland UC, Gilead Pharmasset LLC, Gilead Sciences (GSR) S.R.L., Gilead Sciences (NZ), Gilead Sciences (Shanghai) Consulting Co. Ltd., Gilead Sciences Americas S. de R.L., Gilead Sciences Argentina S.R.L., Gilead Sciences Belgium BVBA, Gilead Sciences Canada Inc., Gilead Sciences Colombia S.A.S., Gilead Sciences Denmark ApS, Gilead Sciences Europe Limited, Gilead Sciences Farmacêutica do Brasil Ltda., Gilead Sciences Finland Oy, Gilead Sciences GesmbH., Gilead Sciences GmbH, Gilead Sciences Hangzhou Pharmaceutical Co. Ltd., Gilead Sciences Hellas EPE, Gilead Sciences Holding LLC, Gilead Sciences Hong Kong Limited, Gilead Sciences Ilac Ticaret Limited Sirketi, Gilead Sciences India Private Limited, Gilead Sciences International Limited, Gilead Sciences Ireland Unlimited Company, Gilead Sciences Israel Limited, Gilead Sciences KK, Gilead Sciences Korea Limited, Gilead Sciences LLC, Gilead Sciences Lda., Gilead Sciences Limited, Gilead Sciences Luxembourg S.a.r.l., Gilead Sciences Malaysia Sdn. Bhd., Gilead Sciences Mexico S. de R.L. de C.V., Gilead Sciences Netherlands BV, Gilead Sciences Norway AS, Gilead Sciences Poland Sp. z o.o., Gilead Sciences Pty. Ltd., Gilead Sciences Russia LLC, Gilead Sciences S.L., Gilead Sciences S.r.l., Gilead Sciences SAS, Gilead Sciences Shanghai Pharmaceutical Technology Co. Ltd., Gilead Sciences Singapore Pte. Ltd., Gilead Sciences Slovakia s.r.o., Gilead Sciences South Africa (Pty) Ltd., Gilead Sciences Sweden AB, Gilead Sciences Switzerland Sarl, Gilead Sciences YM Australia Pty. Ltd., Gilead Sciences s.r.o., Gilead Therapeutics A1 Unlimited Company, Gilead Therapeutics A2 Unlimited Company, Gilead YM ULC, Immunomedics, Immunomedics Inc., KP EU C.V., Kite Pharma, Kite Pharma EU B.V., Kite Pharma Inc., Kite Pharma LLC, MYR, MYR GmbH, MYR Pharmaceuticals France SAS, Myogen, NeXstar Pharmaceuticals, Nimbus Apollo, Nycomed, Pharmasset, Phenex Pharmaceuticals, Raylo Chemicals, Triangle Pharmaceuticals, YM BioSciences, YM BioSciences Australia Pty. Ltd., and neoKite Inc..
Read More
This page (NASDAQ:GILD) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -